Core Insights - Enhabit reported quarterly earnings of 0.04pershare,missingtheZacksConsensusEstimateof0.05 per share, and down from 0.06pershareayearago,representinganearningssurpriseof−20258.2 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.37%, and down from 260.6millionyear−over−year[2]−EnhabithassurpassedconsensusEPSestimatestwotimesoverthelastfourquarters,buthasnotbeatenconsensusrevenueestimatesduringthesameperiod[2]FutureOutlook−TheimmediatepricemovementofEnhabitshareswilldependonmanagement′scommentaryduringtheearningscallandthecompany′searningsoutlook[3][4]−ThecurrentconsensusEPSestimatefortheupcomingquarteris0.06 on revenues of 266.6million,andforthecurrentfiscalyear,itis0.29 on revenues of $1.07 billion [7] - The estimate revisions trend for Enhabit is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance against the market [6] Industry Context - The Medical Services industry, to which Enhabit belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]